Skip to content

Diseases of the Esophagus

Chapter 334 | Part 10: Gastrointestinal System

KEY CLINICAL POINTS

  • Heartburn and regurgitation are hallmark symptoms of GERD, often managed with PPIs and lifestyle modifications.
  • Achalasia is a rare motility disorder characterized by impaired LES relaxation and absent peristalsis, treated with pneumatic dilation or Heller myotomy.
  • Esophageal cancer, particularly adenocarcinoma, is strongly linked to Barrett’s esophagus and GERD, with poor prognosis due to early lymph node metastasis.
  • Infectious esophagitis (Candida, herpesvirus, CMV) is common in immunocompromised patients and requires antifungal/antiviral therapy.
  • Endoscopic evaluation (e.g., manometry, biopsy) is critical for diagnosing motility disorders, Barrett’s esophagus, and malignancies.

1. DEFINITION & OVERVIEW

The esophagus is a muscular tube transporting food to the stomach. Diseases include motility disorders (achalasia, DES), reflux-related conditions (GERD), structural abnormalities (hiatal hernias, rings), and malignancies (adenocarcinoma, squamous cell carcinoma). Key symptoms: heartburn, dysphagia, odynophagia, and regurgitation.

Hiatal Hernia Types

Type Description Clinical Features
Type I (Sliding) Gastroesophageal junction and gastric cardia herniate into the mediastinum Most common; associated with GERD
Type II (Paraesophageal) Stomach herniates into the mediastinum without LES displacement Risk of gastric volvulus; requires surgical repair
Type III (Combined) Sliding and paraesophageal hernia Complex anatomy; higher complication risk
Type IV Other viscera (e.g., colon) herniate into mediastinum Rare; severe complications (e.g., perforation)

1.1 Esophageal Function

The esophagus transports food via peristalsis, with the LES regulating gastric reflux. Dysfunction leads to dysphagia, reflux, or pain. Motility disorders (e.g., achalasia) and inflammation (e.g., GERD) are central to pathophysiology.

1.2 Common Symptoms

Heartburn (pyrosis), regurgitation, chest pain, dysphagia, odynophagia, and globus sensation. Heartburn is often misdiagnosed as cardiac pain but is strongly associated with GERD.

2. EPIDEMIOLOGY

Esophageal cancer incidence: ~21,560 new cases/year in the U.S. (79% men), 16,120 deaths/year. GERD affects 10–15% of adults. Risk factors: obesity, smoking, alcohol, H. pylori, and Barrett’s esophagus.

2.1 Demographics

Adenocarcinoma (linked to GERD/Barrett’s) peaks in white males >60 years. Squamous cell carcinoma (linked to smoking/alcohol) is more common in black males <50 years.

2.2 Risk Factors

Obesity, smoking, alcohol, caustic injury, H. pylori, and chronic GERD. Hiatal hernias increase GERD risk. EoE is more common in atopic individuals (asthma, eczema).

3. ETIOLOGY & PATHOPHYSIOLOGY

GERD: LES dysfunction and reflux of gastric contents. Achalasia: ganglion cell loss in myenteric plexus (autoimmune/HHV-1). Esophageal cancer: chronic inflammation, Barrett’s metaplasia, and oncogenic mutations. Infections (Candida, HSV, CMV) in immunocompromised patients.

Achalasia Subtypes

Subtype Manometric Features Clinical Presentation
Classic Achalasia Minimal esophageal body pressurization, absent peristalsis Progressive dysphagia, weight loss
Esophageal Compression Substantial fluid pressurization, spastic contractions Chest pain, food impaction
Spastic Achalasia Hypercontractile esophagus, tertiary contractions Chest pain, dysphagia

3.1 GERD Pathophysiology

Impaired LES relaxation, increased intra-abdominal pressure, and delayed gastric emptying. Acid and bile reflux cause mucosal injury, leading to esophagitis, strictures, or Barrett’s.

3.2 Achalasia

Autoimmune-mediated ganglion cell loss in the myenteric plexus. Results in absent LES relaxation and peristalsis. Long-standing disease leads to esophageal dilation and squamous cell carcinoma risk.

4. CLINICAL FEATURES

Symptoms vary by disease: GERD (heartburn, regurgitation), achalasia (dysphagia, chest pain), esophageal cancer (weight loss, odynophagia), EoE (chest pain, food impaction). Physical findings: stricture, Barrett’s mucosa, or esophageal masses.

4.1 GERD Symptoms

Heartburn (burning retrosternal pain), regurgitation, dysphagia, and chest pain. May mimic cardiac angina. Often relieved by antacids.

4.2 Esophageal Cancer

Progressive dysphagia, weight loss, odynophagia, and hematemesis. Advanced stages may present with stricture or perforation.

5. DIFFERENTIAL DIAGNOSIS

GERD vs. cardiac ischemia, peptic ulcer disease, EoE, esophageal cancer, or motility disorders (DES, achalasia). Infectious esophagitis (Candida, HSV, CMV) must be differentiated by endoscopic findings and clinical context.

5.1 Cardiac vs. Esophageal Chest Pain

Esophageal pain is non-exertional, relieved by antacids, and associated with regurgitation. Cardiac pain is exertional, unrelieved by antacids, and may radiate to the jaw.

5.2 EoE vs. GERD

EoE presents with food impaction, dysphagia, and eosinophilic inflammation on biopsy. GERD is more common and associated with heartburn and regurgitation.

6. INVESTIGATIONS & DIAGNOSIS

Endoscopy (biopsy for Barrett’s/EoE), manometry (achalasia/DES), barium swallow (hiatal hernia, strictures), and imaging (CT for cancer staging). pH monitoring for GERD.

GERD Diagnostic Criteria

Test Indication Result Interpretation
Endoscopy Suspected Barrett’s or cancer Esophagitis, strictures, or neoplasia
pH Monitoring Atypical symptoms or poor response to PPIs Reflux >6% time indicates GERD
Manometry Dysphagia with no structural cause Impaired LES relaxation or peristalsis

6.1 Diagnostic Tests

Endoscopy: gold standard for visualizing lesions, biopsies, and ruling out cancer. Manometry: detects LES dysfunction (achalasia, DES). Barium swallow: identifies strictures, hiatal hernias, or motility disorders.

6.2 pH Monitoring

Ambulatory 24–96-hour pH monitoring detects acid reflux. Impedance monitoring identifies non-acid reflux. Thresholds: >6% reflux time indicates GERD.

7. MANAGEMENT & TREATMENT

Lifestyle modifications (diet, weight loss), PPIs for GERD, endoscopic dilation/POEM for achalasia, surgery (Heller myotomy) for severe cases. EoE: elimination diets, topical steroids, biologics (dupilumab).

Achalasia Treatment Options

Therapy Success Rate Complications
Pneumatic Dilation 60–90% Perforation (0.5–5%)
Heller Myotomy 62–90% Reflux, dysphagia
Therapy Success Rate Complications
POEM 80–90% GERD, postoperative dysphagia

7.1 GERD Management

PPIs (omeprazole, esomeprazole) as first-line. Lifestyle changes: avoid NSAIDs, alcohol, and fatty foods. Endoscopic therapy for strictures or Barrett’s.

7.2 Achalasia Treatment

Pneumatic dilation (3–4 cm balloon), Heller myotomy (laparoscopic), or POEM. Long-term PPIs to prevent reflux complications.

8. PROGNOSIS & COMPLICATIONS

Esophageal cancer: 5-year survival <10% due to late presentation. Complications of GERD: Barrett’s (17x higher cancer risk), strictures, and aspiration pneumonia. EoE: stricture formation and food impaction.

8.1 Cancer Risk

Barrett’s esophagus: 0.1–0.3% annual cancer risk. Adenocarcinoma incidence increased 6x in 20 years. Early detection via endoscopy and surveillance.

8.2 Complications

GERD: Strictures (treated with dilation), aspiration pneumonia, and esophagitis. Achalasia: Esophageal dilation, perforation, or gastric volvulus.

9. SPECIAL CONSIDERATIONS

Pregnancy: GERD worsens due to hormonal changes; avoid NSAIDs. Elderly: Higher risk of aspiration and delayed diagnosis. Pediatrics: EoE is common in atopic children; avoid allergens. Immunocompromised: Increased risk of infectious esophagitis (Candida, HSV, CMV).

9.1 Pregnancy

GERD management: PPIs (safe in pregnancy), dietary changes, and elevation of the head of the bed. Avoid NSAIDs and antacids with magnesium.

9.2 Pediatrics

EoE: Common in children with atopy (asthma, eczema). Elimination diets (milk, egg, soy) and topical steroids (fluticasone) are first-line. Avoid allergens and monitor for food impaction.

10. KEY POINTS & CLINICAL PEARLS

  1. Heartburn and regurgitation are key symptoms of GERD; treat with PPIs. 2. Achalasia is diagnosed by manometry and managed with dilation/myotomy. 3. Barrett’s esophagus increases adenocarcinoma risk; endoscopic surveillance is critical. 4. EoE is diagnosed by eosinophilic inflammation on biopsy; elimination diets and steroids are effective. 5. Esophageal cancer is often asymptomatic until advanced stages; early endoscopy is essential.